Navigation Links
Moffitt Cancer Center researchers find more clues to causes of breast cancer
Date:10/27/2011

TAMPA, Fla. -- Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) could be targeted as a therapeutic intervention for treating cancer.

Akt, also known as protein kinase B, is one of about 500 protein kinases in the human genome. Kinases are known to regulate the majority of cellular pathways. Akt modifies other proteins chemically and regulates cell proliferation.

"Recent evidence suggests that IKBKE is an oncogenic kinase that participates in malignant transformation and tumor development," said Moffitt senior researcher and lead author Jin Q. Cheng, Ph.D., M.D. "Our study identified Akt as a bona fide substrate of IKBKE and IKBKE direct activation of Akt independent PI3K and revealed a functional link between IKBKE and Akt activation in breast cancer."

Cheng's lab studies a variety of genetic alterations and their molecular mechanisms in both ovarian and breast cancer, particularly on their effect on the molecules that are regulated by Akt and the small molecule inhibitors of Akt.

"We found that inhibition of Akt suppresses IKBKE's oncogenic transformation," said Cheng. "This is significant because overexpression of IKBKE and activation of Akt has been observed in more than 50 percent of human cancers. Akt inhibitors targeting PH domain do not have inhibitory effect on IKBKE-induced Akt."

The researchers experimented with a variety of inhibitors currently being used in clinical trials.

The laboratory study utilized breast cancer cell lines from received from patient donors at Moffitt and cell lines received from Harvard University and Johns Hopkins University. The work was supported by a National Institutes of Health grant and a grant f
'/>"/>

Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
3. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
4. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
5. Enhancing arrest of cell growth to treat cancer in mice
6. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
7. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
8. Low forms of cyclin E reduce breast cancer drugs effectiveness
9. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
10. Soft drinks may increase risk of pancreatic cancer
11. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Ticket Down ... Inter Milan tickets in Berkeley at California Memorial Stadium. ... new fans of football, the organizers of the 2014 Guinness ... club teams to North America. With teams representing La Liga, ... will bring some of the best football players from around ...
(Date:7/25/2014)... 2014 Parker Waichman LLP, a national ... comments on a recent tobacco lawsuit in which a ... billion in punitive damages. Cynthia Robinson brought the lawsuit ... case is Cynthia Robinson v. R.J. Reynolds Tobacco Company ... Circuit Court, Escambia County, Florida; Case Number 2008 CA ...
(Date:7/25/2014)... nearly 27,000 older adults on five continents found that ... on a simple test that measures how fast people ... tested positive for pre-dementia were twice as likely as ... led by scientists at Albert Einstein College of ... Center , was published online on July 16, 2014 ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 Hastings ... offering discount attorney’s fees with regard to personal ... Hastings provide a wide range of legal services for ... the negligence of another individual or corporation. Free initial ... determining the validity of a potential personal injury ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 As thousands ... in U.S. courts, Bernstein Liebhard LLP notes that the ... by the consumer advocacy group, Public Citizen, to order ... a letter dated May 1, 2014, and released to ... group’s petition for a ban on the marketing of ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4
... may be at increased risk of experiencing a life-threatening ... with low POD had significantly more emergency department visits, ... 2 year study period than those with normal dyspnoea ... to be older, female and generally had suffered from ...
... well perceived that smoking accelerates the risk of heart disease, ... capacity for the development of a heart attack.This is because ... immediate impact on the cardiovascular system.// ,In a study ... smoked a cigarette within six hours of developing symptoms had ...
... Johns Hopkins University School of Medicine have recently found that ... brain that lets us stop smelling something, even though the ... recent issue of the journal Science show that a protein ... main job of these reurons is to detect smells and ...
... bring to notice that sensible drinking could reduce their risk ... of excess. In a new leaflet, the Stroke Association says ... caused by blood clots blocking arteries - which account for ... ,Alcohol thins the blood, so can prevents the formation ...
... a leafy plant native to the South Sea Islands. It ... cases of liver diseases. The herb is commonly used by ... stress and muscle spasms. According to experts, the herb behaves ... not chemically related. ,Benzodiazepines have been shown to be ...
... first isolated a decade ago at Johns Hopkins, may ... study shows that the compound, sulphoraphane, helps cells defend ... and toxic molecules called oxidants.// , Unlike standard anti-oxidants ... combat, broccoli’s compound is a covert operative that works ...
Cached Medicine News:
(Date:7/24/2014)... July 24, 2014  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat ... fiscal 2015 first quarter ended June 30, 2014.  ...  PC Neuromodulation System grew 19% to $4.1 million, ... quarter of the prior year.  Total revenue for ...
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... DIEGO, Jan. 10, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Linda Amper, Ph.D., as Senior Vice President of Human ... Economics & Outcomes Research (HEOR), and John Womelsdorf, Ph.D., ... will strengthen the management team as the Company prepares ...
... Calif., Jan. 10, 2011 OncoMed Pharmaceuticals, Inc., ... today announced that patient dosing has commenced in a Phase ... tumor cancers.   OMP-59R5 is a monoclonal antibody ... to specifically block these targets to enter human studies.  The ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Key Additions to Management Team 2Optimer Pharmaceuticals Announces Key Additions to Management Team 3Optimer Pharmaceuticals Announces Key Additions to Management Team 4OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 2OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 3
... StressVue puts leading-edge stress testing within reach ... or clinic to the most advanced cardiology ... flat panel monitor with options for a ... printer for continuous printing. StressVue is designed ...
... Philip's EASITrak 12 gives you the ... informed treatment decisions for your patients with ... ,Designed with the EASI Lead System, this ... leads to capture a derived 12-lead ECG. ...
A component of the 3M Littmann Electronic Stethoscope Model 4000...
... monitor captures the data you need while ... only five electrodes, the DigiTrak Plus provides ... patient test, which can be up to ... Three channels of ECG recording and a ...
Medicine Products: